Consort Medical PLC Director/PDMR Shareholding (7284Y)

TIDMCSRT

RNS Number : 7284Y

Consort Medical PLC

10 September 2015

10 September 2015

Consort Medical plc

Notification of Transactions of Directors or

Persons Discharging Managerial Responsibility and Connected Persons

DTR 3.1.4

On 10 September 2015 pursuant to the rules of the Consort Medical plc Deferred Bonus Plan 2010, the following Directors/persons discharging managerial responsibilities ("PDMRs") of Consort Medical plc (the "Company"), were granted immediately exercisable awards over ordinary shares at a share price of GBP9.6183 in the Company ("Shares").

Deferred Bonus Share Award

 
 Director/PDMR       Number of Shares 
 Jon Glenn                6,880 
                    ----------------- 
 Lisa King                2,341 
                    ----------------- 
 Keyvan Djamarani         1,959 
                    ----------------- 
 

Each of the awards was granted as a nil cost option.

The awards were made following the approval given at the Annual General Meeting held on 3 September 2015 for an adjustment in respect of the vested and exercised 2011 Long Term Incentive Plan and 2011 Deferred Bonus Plan awards. The adjustments are designed to ensure that participants are unaffected by the impact of the rights issue undertaken in 2014.

   Enquiries:        I Ward 01442 867920 

Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, UK; in Monheim and Zwickau, Germany; and in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSZBLFFEKFBBBQ

(END) Dow Jones Newswires

September 10, 2015 10:08 ET (14:08 GMT)